Skip to content

Psilocybin: all studies

Page 335 of 440: studies 3,341 to 3,350 of 4,400, newest first. Back to the psilocybin overview

Research

Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis

Research Square August 19, 2025 Haley D M Schuman, Julie M Deleemans, Tina Nguyen et al. preprint

Abstract Background Psychedelic-assisted therapy (PAT) is gaining attention as a potential treatment for cancer-related psychosocial symptoms. While growing evidence highlights its promise, little is known about how different stakeholder groups perceive its use in oncology and palliative care. Objectives This study aimed to assess stakeholder-specific perspectives on PAT, including attitudes,...

Psychedelics’ Intoxicating Impact and Behavioural Dynamics

Pharmaceutical Science August 19, 2025 Afshan Zeeshan Wasti

Psychedelics such as psilocybin and lysergic acid diethylamide upset the brain networks involved in self-awareness and emotion and may lead to altered perception, cognition, and social behaviour, although unsupervised use is still dangerous due to their unpredictable psychological and physiological effects. These drugs cause emotions to be amplified, the ego to dissolve, and sensory vividness...

Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions

Psychiatry Research August 18, 2025 Ilenia Rosa, L. Padula, Francesco Semeraro et al. 2 citations

Depression is a prevalent and heterogeneous disorder with significant personal and social consequences. The rise of treatment-resistant depression (TRD) challenges traditional approaches and underscores the need for a broader neurobiological perspective. When monoaminergic modulation proves insufficient, clinical guidelines increasingly turn to non-monoaminergic interventions such as...

DOI: 10.1016/j.psychres.2025.116697 (opens in new tab) Endocannabinoid system Depression economics Psychological intervention Resistance ecology +2

Psicodélicos e plasticidade cerebral no tratamento do transtorno de estresse pós-traumático

Brazilian Journal of Implantology and Health Sciences August 14, 2025 A. Silva, Érika Barros Teixeira da Cruz, Samuel Cândido Freres et al.

O transtorno de estresse pós-traumático (TEPT) é uma condição psiquiátrica caracterizada por sintomas persistentes após vivência de eventos traumáticos, incluindo revivescências, hipervigilância e esquiva. Estudos recentes têm apontado o uso de psicodélicos, como MDMA e psilocibina, como potenciais coadjuvantes no tratamento, devido à sua capacidade de promover neuroplasticidade e facilitar a...

Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms

Psychiatry and Clinical Psychopharmacology August 14, 2025 Nadav Liam Modlin, Jessica L Maples-Keller, Maria Sarang et al.

Background: Current trauma treatment options often fail to meet patients' needs. Despite the availability of established interventions, many trauma treatments fail to adequately meet patients' needs. In parallel, there has been renewed scientific and public interest in the therapeutic potential of psychedelics and related compounds, accompanied by increasing unsupervised use. This underscores...

DOI: 10.5152/pcp.2025.24934 (opens in new tab) Psychotherapist Psychological trauma Clinical psychology

Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi

Journal of AOAC International August 13, 2025 Kimberley Foster, Isaac Morrison, S. Daniel et al. 4 citations

Abstract Background The consumption of dried fruiting bodies of Psilocybe cubensis can be traced over centuries, guided by Mesoamerican curanderas, Western medical practitioners, and fungal enthusiasts, all seeking mental wellbeing. There is a notable resurgence in interest both in the fungal biomass and psilocybin, the psychoactive tryptamine, despite the global regulatory restrictions,...

Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent

Psychopharmacology Bulletin August 12, 2025 Anna Mori-Kreiner, Arpit Aggarwal, Meelie Bordoloi 1 citation

Objective Hallucinogen-persisting Perception Disorder (HPPD) is a rare condition characterized by the re-experiencing of one or more perceptual symptoms that an individual experienced while intoxicated with a hallucinogenic substance when the individual is sober. While there are several case reports of HPPD in adult patients, there is a scarcity of documented cases in children and adolescents....

DOI: 10.64719/pb.4525 (opens in new tab) Full text (opens in new tab) Perception Hallucinogen Clinical psychology Plant-based medicinal research

John Allegro and the Psychedelic Mysteries Hypothesis

Religions August 9, 2025 Richard S. Ascough 4 citations

John Allegro’s The Sacred Mushroom and the Cross posits that early Christianity derived from fertility cults involving psychedelic mushroom use. Though widely discredited by scholars when it was first published, the theory persists in popular culture and entheogenic discourse. This article evaluates the scholarly reception, methodological flaws, and enduring cultural impact of Allegro’s thesis,...

DOI: 10.3390/rel16081029 (opens in new tab) Scholarship Curiosity Epistemology Aesthetics +1

Intersecting Psychedelic Pharmacology and Gut-Brain Axis Signaling in Neurodegenerative Disorders

JUNIOR RESEARCHERS August 8, 2025 Harsha S. Krishna

Neurodegenerative diseases are marked by progressive neuronal loss, inflammation, and impaired plasticity. Although existing treatments provide limited protection for the brain or ability to slow disease progression, emerging research highlights the gut-brain axis and psychedelics as promising new areas for therapeutic development. The gut microbiome, a metabolically active ecosystem,...

Psychedelic Awakenings

August 8, 2025 Gary Laderman

Chapter 7 examines the rich and surprising history of psychedelics and religious life in the Americas, and in modern American life. The sacred drugs du jour now and likely into the future are psychedelics. LSD, psilocybin, MDMA, DMT, ayahuasca, and mescaline are several of the organic and synthetic psychoactive, serotonergic agents that have entered popular consciousness and are in the process...